Johnson & Johnson $JNJ Position Cut by Aire Advisors LLC

Aire Advisors LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 5.7% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 9,535 shares of the company’s stock after selling 577 shares during the quarter. Aire Advisors LLC’s holdings in Johnson & Johnson were worth $1,456,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new stake in shares of Johnson & Johnson during the first quarter valued at about $218,000. GAMMA Investing LLC raised its stake in shares of Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Kiley Juergens Wealth Management LLC raised its position in Johnson & Johnson by 2.5% in the first quarter. Kiley Juergens Wealth Management LLC now owns 17,909 shares of the company’s stock worth $2,970,000 after acquiring an additional 435 shares in the last quarter. Finally, Community Bank N.A. raised its position in Johnson & Johnson by 4.0% in the first quarter. Community Bank N.A. now owns 47,656 shares of the company’s stock worth $7,903,000 after acquiring an additional 1,835 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $193.27 on Friday. The stock’s 50-day moving average price is $180.49 and its two-hundred day moving average price is $164.80. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $465.45 billion, a PE ratio of 18.65, a PEG ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of several research reports. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.